Fusion Antibodies, a UK-based contract research organisation and MAB Discovery, a unique antibody discovery company, have announced their intention to enter into a research and licence agreement in the field of monoclonal antibodies.

Within the scope of this collaboration, Fusion Antibodies will apply our proprietary CDRx Multiplex humanisation platform to generate therapeutic antibodies, selected and produced by MAB Discovery, who will provide high-quality humanised antibodies ready for further development to potential partners.

“Through this collaboration we are able to create synergies and provide clients with perfect antibody candidates. They will get access to rapid discovery and development of new antibodies through MAB Discovery’s unique immunization and B cell cloning technology. MAB Discovery has developed a rabbit-based platform that produces monoclonal antibodies with unprecedented epitope coverage and potency,” said Dr Paul Kerr, managing director, Fusion Antibodies.

“We are very pleased to be working with Fusion Antibodies, a well-respected antibody engineering firm with strong expertise in humanization,” said Dr. Stephan Fischer, chief executive officer of MAB Discovery. “The planned collaboration will enable us to provide our customers added value by offering high-quality humanized antibodies that are ready to be validated and brought into development. We also expect that combining our technologies will reduce the time from target to clinical candidate.”

MAB Discovery is focused on creating a vast repertoire of high quality monoclonal antibodies in terms of potency and epitope coverage for its clients, who include biotech and pharmaceutical companies such as Sanofi, GenMab A/S, Synthon Biopharmaceuticals and others.